Genetic Technologies Receives Approval to Sell BrevaGen in California | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has been granted a license from California allowing the Australian firm to sell its BrevaGen breast cancer test in that state.

The Laboratory Field Services Unit of the California Department of Public Health has granted a license to Genetic Technologies' Australian-based laboratory, the firm said. The state represents about 11 percent of the total number of breast cancer incidents in the US with more than 25,000 new cases of breast cancer diagnosed annually, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.